New Hope For Dexpramipexole?

Biogen Asked in Lawsuit to Return Biosamples to Knopp.

Biogen, based in Weston, Massachusetts, said in January that the drug, dexpramipexole, failed to show any efficacy in a large clinical trial, in the third and final phase of studies generally required for regulatory approval. The drug had been thought to potentially slow the progression of ALS after promising signs in earlier studies.

Knopp’s own analyses of the trial results found “subgroups of the total study population that exhibited slower disease progression and reduced mortality when treated with dexpramipexole,” according to the complaint. Knopp said it wants the patients’ samples from the trial to help it continue to try to develop the medicine itself.